409 related articles for article (PubMed ID: 28806782)
1. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
2. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.
Maynard J; Ricketts SA; Gendrin C; Dudley P; Davies BR
Mol Imaging Biol; 2013 Aug; 15(4):476-85. PubMed ID: 23344784
[TBL] [Abstract][Full Text] [Related]
3. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
Kelly CJ; Hussien K; Muschel RJ
Nucl Med Biol; 2012 Oct; 39(7):986-92. PubMed ID: 22682985
[TBL] [Abstract][Full Text] [Related]
4. The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor.
Maynard J; Emmas SA; Blé FX; Barjat H; Lawrie E; Hancox U; Oakes D; Polanska UM; Barry ST
EJNMMI Res; 2016 Dec; 6(1):62. PubMed ID: 27515445
[TBL] [Abstract][Full Text] [Related]
5. Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.
Hudson K; Hancox UJ; Trigwell C; McEwen R; Polanska UM; Nikolaou M; Morentin Gutierrez P; Avivar-Valderas A; Delpuech O; Dudley P; Hanson L; Ellston R; Jones A; Cumberbatch M; Cosulich SC; Ward L; Cruzalegui F; Green S
Mol Cancer Ther; 2016 May; 15(5):877-89. PubMed ID: 26839307
[TBL] [Abstract][Full Text] [Related]
6. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
[TBL] [Abstract][Full Text] [Related]
7. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
8. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.
McKinley ET; Bugaj JE; Zhao P; Guleryuz S; Mantis C; Gokhale PC; Wild R; Manning HC
Clin Cancer Res; 2011 May; 17(10):3332-40. PubMed ID: 21257723
[TBL] [Abstract][Full Text] [Related]
9. [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.
Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Bzorek M; Jensen PB; Højgaard L; Sehested M; Kjær A
PLoS One; 2013; 8(1):e53410. PubMed ID: 23308217
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.
Barlaam B; Cosulich S; Delouvrié B; Ellston R; Fitzek M; Germain H; Green S; Hancox U; Harris CS; Hudson K; Lambert-van der Brempt C; Lebraud H; Magnien F; Lamorlette M; Le Griffon A; Morgentin R; Ouvry G; Page K; Pasquet G; Polanska U; Ruston L; Saleh T; Vautier M; Ward L
Bioorg Med Chem Lett; 2015 Nov; 25(22):5155-62. PubMed ID: 26475521
[TBL] [Abstract][Full Text] [Related]
11. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.
Kaira K; Serizawa M; Koh Y; Takahashi T; Yamaguchi A; Hanaoka H; Oriuchi N; Endo M; Ohde Y; Nakajima T; Yamamoto N
Lung Cancer; 2014 Feb; 83(2):197-204. PubMed ID: 24365102
[TBL] [Abstract][Full Text] [Related]
12. Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.
Cullinane C; Waldeck KL; Binns D; Bogatyreva E; Bradley DP; de Jong R; McArthur GA; Hicks RJ
Nucl Med Biol; 2014 Feb; 41(2):148-54. PubMed ID: 24332383
[TBL] [Abstract][Full Text] [Related]
13. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Ma WW; Jacene H; Song D; Vilardell F; Messersmith WA; Laheru D; Wahl R; Endres C; Jimeno A; Pomper MG; Hidalgo M
J Clin Oncol; 2009 Jun; 27(16):2697-704. PubMed ID: 19380450
[TBL] [Abstract][Full Text] [Related]
14. PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8
Carnevalli LS; Sinclair C; Taylor MA; Gutierrez PM; Langdon S; Coenen-Stass AML; Mooney L; Hughes A; Jarvis L; Staniszewska A; Crafter C; Sidders B; Hardaker E; Hudson K; Barry ST
J Immunother Cancer; 2018 Dec; 6(1):158. PubMed ID: 30587236
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice.
McLarty K; Moran MD; Scollard DA; Chan C; Sabha N; Mukherjee J; Guha A; McLaurin J; Nitz M; Houle S; Wilson AA; Reilly RM; Vasdev N
Nucl Med Biol; 2011 Oct; 38(7):953-9. PubMed ID: 21982567
[TBL] [Abstract][Full Text] [Related]
16. Dynamic 2-Deoxy-2-[
Kristian A; Holtedahl JE; Torheim T; Futsaether C; Hernes E; Engebraaten O; Mælandsmo GM; Malinen E
Mol Imaging Biol; 2017 Apr; 19(2):271-279. PubMed ID: 27541026
[TBL] [Abstract][Full Text] [Related]
17. Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG) and 3'-[18F]fluoro-3'-deoxythymidine (FLT).
Molthoff CF; Klabbers BM; Berkhof J; Felten JT; van Gelder M; Windhorst AD; Slotman BJ; Lammertsma AA
Mol Imaging Biol; 2007; 9(6):340-7. PubMed ID: 17643202
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism.
Tseng JC; Narayanan N; Ho G; Groves K; Delaney J; Bao B; Zhang J; Morin J; Kossodo S; Rajopadhye M; Peterson JD
PLoS One; 2017; 12(8):e0182689. PubMed ID: 28792505
[TBL] [Abstract][Full Text] [Related]
20. Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.
Vergez S; Delord JP; Thomas F; Rochaix P; Caselles O; Filleron T; Brillouet S; Canal P; Courbon F; Allal BC
Clin Cancer Res; 2010 Sep; 16(17):4434-45. PubMed ID: 20660574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]